\n\nUS4128654<\/a><\/td>\n | 10 Feb 1978<\/td>\n | 5 Dec 1978<\/td>\n | E. I. Du Pont De Nemours And Company<\/td>\n | 5-Halomethyl-3-phenyl-2-oxazolidinones<\/td>\n<\/tr>\n |
\nUS4250318<\/a><\/td>\n | 9 Aug 1978<\/td>\n | 10 Feb 1981<\/td>\n | Delalande S.A.<\/td>\n | Novel 5-hydroxymethyl oxazolidinones, the method of preparing them and their application in therapeutics<\/td>\n<\/tr>\n |
\nUS4340606<\/a><\/td>\n | 23 Oct 1980<\/td>\n | 20 Jul 1982<\/td>\n | E. I. Du Pont De Nemours And Company<\/td>\n | 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents<\/td>\n<\/tr>\n |
\nUS4461773<\/a><\/td>\n | 5 Jan 1984<\/td>\n | 24 Jul 1984<\/td>\n | E. I. Dupont De Nemours And Company<\/td>\n | P-Oxooxazolidinylbenzene compounds as antibacterial agents<\/td>\n<\/tr>\n |
\nUS4476136<\/a><\/td>\n | 24 Feb 1982<\/td>\n | 9 Oct 1984<\/td>\n | Delalande S.A.<\/td>\n | Aminomethyl-5 oxazolidinic derivatives and therapeutic use thereof<\/td>\n<\/tr>\n |
\nUS4948801<\/a><\/td>\n | 29 Jul 1988<\/td>\n | 14 Aug 1990<\/td>\n | E. I. Du Pont De Nemours And Company<\/td>\n | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents<\/td>\n<\/tr>\n |
\nUS5523403<\/a><\/td>\n | 22 May 1995<\/td>\n | 4 Jun 1996<\/td>\n | The Upjohn Company<\/td>\n | Tropone-substituted phenyloxazolidinone antibacterial agents<\/td>\n<\/tr>\n |
\nUS5565571<\/a><\/td>\n | 28 Apr 1994<\/td>\n | 15 Oct 1996<\/td>\n | The Upjohn Company<\/td>\n | Substituted aryl- and heteroaryl-phenyloxazolidinones<\/td>\n<\/tr>\n |
\nUS5652238<\/a><\/td>\n | 27 Sep 1994<\/td>\n | 29 Jul 1997<\/td>\n | Pharmacia & Upjohn Company<\/td>\n | Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones<\/td>\n<\/tr>\n |
\nUS5688792<\/a><\/td>\n | 16 Aug 1994<\/td>\n | 18 Nov 1997<\/td>\n | Pharmacia & Upjohn Company<\/td>\n | Substituted oxazine and thiazine oxazolidinone antimicrobials<\/td>\n<\/tr>\n |
\nUS6365751<\/a><\/td>\n | 17 Apr 2001<\/td>\n | 2 Apr 2002<\/td>\n | Zeneca Ltd.<\/td>\n | Antibiotic oxazolidinone derivatives<\/td>\n<\/tr>\n |
\nUS6627646<\/a>\u00a0*<\/td>\n | 17 Jul 2001<\/td>\n | 30 Sep 2003<\/td>\n | Sepracor Inc.<\/td>\n | Norastemizole polymorphs<\/td>\n<\/tr>\n |
\nUS6689779<\/a><\/td>\n | 18 May 2001<\/td>\n | 10 Feb 2004<\/td>\n | Dong A Pharm. Co., Ltd.<\/td>\n | Oxazolidinone derivatives and a process for the preparation thereof<\/td>\n<\/tr>\n |
\nUS7129259<\/a><\/td>\n | 1 Dec 2004<\/td>\n | 31 Oct 2006<\/td>\n | Rib-X Pharmaceuticals, Inc.<\/td>\n | Halogenated biaryl heterocyclic compounds and methods of making and using the same<\/td>\n<\/tr>\n |
\nUS7141583<\/a><\/td>\n | 23 Apr 2001<\/td>\n | 28 Nov 2006<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinone derivatives with antibiotic activity<\/td>\n<\/tr>\n |
\nUS7144911<\/a><\/td>\n | 24 Dec 2003<\/td>\n | 5 Dec 2006<\/td>\n | Deciphera Pharmaceuticals Llc<\/td>\n | Anti-inflammatory medicaments<\/td>\n<\/tr>\n |
\nUS7202257<\/a><\/td>\n | 6 Jul 2004<\/td>\n | 10 Apr 2007<\/td>\n | Deciphera Pharmaceuticals, Llc<\/td>\n | Anti-inflammatory medicaments<\/td>\n<\/tr>\n |
\nUS7396847<\/a><\/td>\n | 9 Sep 2002<\/td>\n | 8 Jul 2008<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinone and\/or isoxazoline as antibacterial agents<\/td>\n<\/tr>\n |
\nUS7462633<\/a><\/td>\n | 29 Jun 2004<\/td>\n | 9 Dec 2008<\/td>\n | Merck & Co., Inc.<\/td>\n | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof<\/td>\n<\/tr>\n |
\nUS7473699<\/a><\/td>\n | 25 Feb 2003<\/td>\n | 6 Jan 2009<\/td>\n | Astrazeneca Ab<\/td>\n | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents<\/td>\n<\/tr>\n |
\nUS7498350<\/a><\/td>\n | 24 Nov 2003<\/td>\n | 3 Mar 2009<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinones as antibacterial agents<\/td>\n<\/tr>\n |
\nUS7816379<\/a><\/td>\n | 17 Dec 2004<\/td>\n | 19 Oct 2010<\/td>\n | Dong-A Pharm. Co., Ltd.<\/td>\n | Oxazolidinone derivatives<\/td>\n<\/tr>\n |
\nUS20020115669<\/a><\/td>\n | 29 Aug 2001<\/td>\n | 22 Aug 2002<\/td>\n | Wiedeman Paul E.<\/td>\n | Oxazolidinone chemotherapeutic agents<\/td>\n<\/tr>\n |
\nUS20030166620<\/a><\/td>\n | 18 May 2001<\/td>\n | 4 Sep 2003<\/td>\n | Jae-Gul Lee<\/td>\n | Novel oxazolidinone derivatives and a process for the preparation thereof<\/td>\n<\/tr>\n |
\nUS20040180906<\/a><\/td>\n | 24 Dec 2003<\/td>\n | 16 Sep 2004<\/td>\n | Flynn Daniel L<\/td>\n | Anti-inflammatory medicaments<\/td>\n<\/tr>\n |
\nUS20050038092<\/a><\/td>\n | 29 Jun 2004<\/td>\n | 17 Feb 2005<\/td>\n | Yasumichi Fukuda<\/td>\n | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof<\/td>\n<\/tr>\n |
\nUS20050107435<\/a><\/td>\n | 9 Sep 2002<\/td>\n | 19 May 2005<\/td>\n | Gravestock Michael B.<\/td>\n | Oxazolidinone and\/or isoxazoline as antibacterial agents<\/td>\n<\/tr>\n |
\nUS20050288286<\/a><\/td>\n | 6 Jul 2004<\/td>\n | 29 Dec 2005<\/td>\n | Flynn Daniel L<\/td>\n | Anti-inflammatory medicaments<\/td>\n<\/tr>\n |
\nUS20060116386<\/a><\/td>\n | 24 Nov 2003<\/td>\n | 1 Jun 2006<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinones as antibacterial agents<\/td>\n<\/tr>\n |
\nUS20060116400<\/a><\/td>\n | 24 Nov 2003<\/td>\n | 1 Jun 2006<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinone and\/or isoxazoline derivatives as antibacterial agents<\/td>\n<\/tr>\n |
\nUS20060270637<\/a><\/td>\n | 24 Feb 2004<\/td>\n | 30 Nov 2006<\/td>\n | Astrazeneca Ab<\/td>\n | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents<\/td>\n<\/tr>\n |
\nUS20070155798<\/a><\/td>\n | 17 Dec 2004<\/td>\n | 5 Jul 2007<\/td>\n | Dong-A Pharm. Co., Ltd.<\/td>\n | Novel oxazolidinone derivatives<\/td>\n<\/tr>\n |
\nUS20070185132<\/a><\/td>\n | 29 Jun 2004<\/td>\n | 9 Aug 2007<\/td>\n | Yasumichi Fukuda<\/td>\n | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo<\/td>\n<\/tr>\n |
\nUS20070191336<\/a><\/td>\n | 23 Dec 2004<\/td>\n | 16 Aug 2007<\/td>\n | Flynn Daniel L<\/td>\n | Anti-inflammatory medicaments<\/td>\n<\/tr>\n |
\nUS20070203187<\/a><\/td>\n | 22 Jan 2007<\/td>\n | 30 Aug 2007<\/td>\n | Merck & Co., Inc.<\/td>\n | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof<\/td>\n<\/tr>\n |
\nUS20070208062<\/a><\/td>\n | 24 May 2005<\/td>\n | 6 Sep 2007<\/td>\n | Astrazeneca Ab<\/td>\n | 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections<\/td>\n<\/tr>\n |
\nUS20080021012<\/a><\/td>\n | 24 May 2005<\/td>\n | 24 Jan 2008<\/td>\n | Astrazeneca Ab<\/td>\n | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents<\/td>\n<\/tr>\n |
\nUS20080021071<\/a><\/td>\n | 24 May 2005<\/td>\n | 24 Jan 2008<\/td>\n | Astrazeneca Ab<\/td>\n | 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents<\/td>\n<\/tr>\n |
\nUS20080064689<\/a><\/td>\n | 24 May 2004<\/td>\n | 13 Mar 2008<\/td>\n | Astrazeneca Ab<\/td>\n | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents<\/td>\n<\/tr>\n |
\nUS20090018123<\/a><\/td>\n | 19 Jun 2006<\/td>\n | 15 Jan 2009<\/td>\n | Milind D Sindkhedkar<\/td>\n | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation<\/td>\n<\/tr>\n |
\nUS20090192197<\/a><\/td>\n | 16 Sep 2008<\/td>\n | 30 Jul 2009<\/td>\n | Dong-A Pharm. Co., Ltd.<\/td>\n | Novel oxazolidinone derivatives<\/td>\n<\/tr>\n |
\nUS20100093669<\/a><\/td>\n | 9 Oct 2009<\/td>\n | 15 Apr 2010<\/td>\n | Trius Therapeutics<\/td>\n | Methods for preparing oxazolidinones and compositions containing them<\/td>\n<\/tr>\n |
\nUS20100227839<\/a><\/td>\n | 3 Feb 2010<\/td>\n | 9 Sep 2010<\/td>\n | Trius Therapeutics<\/td>\n | Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate<\/td>\n<\/tr>\n |
\nAU2004299413A1<\/a><\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | Title not available<\/td>\n<\/tr>\n |
\nAU2009200606A1<\/a><\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | Title not available<\/td>\n<\/tr>\n |
\nCA2549062A1<\/a><\/td>\n | 17 Dec 2004<\/td>\n | 30 Jun 2005<\/td>\n | Chong Hwan Cho<\/td>\n | Novel oxazolidinone derivatives<\/td>\n<\/tr>\n |
\nCN101982468A<\/a><\/td>\n | 17 Dec 2004<\/td>\n | 2 Mar 2011<\/td>\n | \u4e1c\u4e9a\u5236\u836f\u682a\u5f0f\u4f1a\u793e<\/td>\n | Novel oxazolidinone derivatives and pharmaceutical compositions comprising the derivatives<\/td>\n<\/tr>\n |
\nEP0312000A1<\/a><\/td>\n | 12 Oct 1988<\/td>\n | 19 Apr 1989<\/td>\n | The Du Pont Merck Pharmaceutical Company<\/td>\n | Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents<\/td>\n<\/tr>\n |
\nEP0352781A2<\/a><\/td>\n | 27 Jul 1989<\/td>\n | 31 Jan 1990<\/td>\n | The Du Pont Merck Pharmaceutical Company<\/td>\n | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents<\/td>\n<\/tr>\n |
\nEP1699784A1<\/a><\/td>\n | 17 Dec 2004<\/td>\n | 13 Sep 2006<\/td>\n | Dong-A Pharmaceutical Co., Ltd.<\/td>\n | Novel oxazolidinone derivatives<\/td>\n<\/tr>\n |
\nEP2305657A2<\/a><\/td>\n | 17 Dec 2004<\/td>\n | 6 Apr 2011<\/td>\n | Dong-A Pharmaceutical Co., Ltd.<\/td>\n | Oxazolidinone derivatives<\/td>\n<\/tr>\n |
\nEP2435051A1<\/a><\/td>\n | 27 May 2010<\/td>\n | 4 Apr 2012<\/td>\n | Trius Therapeutics<\/td>\n | Oxazolidinone containing dimer compounds, compositions and methods to make and use<\/td>\n<\/tr>\n |
\nIN236862A1<\/a><\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | Title not available<\/td>\n<\/tr>\n |
\nJPS5799576A<\/a><\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | Title not available<\/td>\n<\/tr>\n |
\nKR20110071107A<\/a><\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | Title not available<\/td>\n<\/tr>\n |
\nNZ547928A<\/a><\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | Title not available<\/td>\n<\/tr>\n |
\nNZ575842A<\/a><\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | Title not available<\/td>\n<\/tr>\n |
\nWO1993009103A1<\/a><\/td>\n | 5 Oct 1992<\/td>\n | 13 May 1993<\/td>\n | Upjohn Co<\/td>\n | Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents<\/td>\n<\/tr>\n |
\nWO1993023384A1<\/a><\/td>\n | 21 Apr 1993<\/td>\n | 25 Nov 1993<\/td>\n | Michael Robert Barbachyn<\/td>\n | Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials<\/td>\n<\/tr>\n |
\nWO1995007271A1<\/a><\/td>\n | 16 Aug 1994<\/td>\n | 16 Mar 1995<\/td>\n | Michael R Barbachyn<\/td>\n | Substituted oxazine and thiazine oxazolidinone antimicrobials<\/td>\n<\/tr>\n |
\nWO1995014684A1<\/a><\/td>\n | 27 Sep 1994<\/td>\n | 1 Jun 1995<\/td>\n | Michel R Barbachyn<\/td>\n | Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones<\/td>\n<\/tr>\n |
\nWO2001094342A1<\/a><\/td>\n | 18 May 2001<\/td>\n | 13 Dec 2001<\/td>\n | Cho Jong Hwan<\/td>\n | Novel oxazolidinone derivatives and a process for the preparation thereof<\/td>\n<\/tr>\n |
\nWO2002081470A1<\/a><\/td>\n | 3 Apr 2002<\/td>\n | 17 Oct 2002<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinones containing a sulfonimid group as antibiotics<\/td>\n<\/tr>\n |
\nWO2003022824A1<\/a><\/td>\n | 9 Sep 2002<\/td>\n | 20 Mar 2003<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinone and\/or isoxazoline as antibacterial agents<\/td>\n<\/tr>\n |
\nWO2003035648A1<\/a><\/td>\n | 23 Oct 2002<\/td>\n | 1 May 2003<\/td>\n | Astrazeneca Ab<\/td>\n | Aryl substituted oxazolidinones with antibacterial activity<\/td>\n<\/tr>\n |
\nWO2003047358A1<\/a><\/td>\n | 2 Dec 2002<\/td>\n | 12 Jun 2003<\/td>\n | Vaughan Leslie Crow<\/td>\n | Cheese flavour ingredient and method of its production<\/td>\n<\/tr>\n |
\nWO2003072575A1<\/a><\/td>\n | 25 Feb 2003<\/td>\n | 4 Sep 2003<\/td>\n | Astrazeneca Ab<\/td>\n | 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents<\/td>\n<\/tr>\n |
\nWO2003072576A2<\/a><\/td>\n | 25 Feb 2003<\/td>\n | 4 Sep 2003<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them<\/td>\n<\/tr>\n |
\nWO2004048350A2<\/a><\/td>\n | 24 Nov 2003<\/td>\n | 10 Jun 2004<\/td>\n | Astrazeneca Ab<\/td>\n | Oxazolidinones as antibacterial agents<\/td>\n<\/tr>\n |
\nWO2004083205A1<\/a><\/td>\n | 16 Mar 2004<\/td>\n | 30 Sep 2004<\/td>\n | Astrazeneca Ab<\/td>\n | Antibacterial 1, 3- oxazolidin -2- one derivatives<\/td>\n<\/tr>\n |
\nWO2005005398A2<\/a><\/td>\n | 29 Jun 2004<\/td>\n | 20 Jan 2005<\/td>\n | Yasumichi Fukuda<\/td>\n | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof<\/td>\n<\/tr>\n |
\nWO2005051933A1<\/a><\/td>\n | 23 Nov 2004<\/td>\n | 9 Jun 2005<\/td>\n | Vijay Kumar Kaul<\/td>\n | An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby<\/td>\n<\/tr>\n |
\nWO2005058886A1<\/a><\/td>\n | 17 Dec 2004<\/td>\n | 30 Jun 2005<\/td>\n | Dong A Pharm Co Ltd<\/td>\n | Novel oxazolidinone derivatives<\/td>\n<\/tr>\n |
\nWO2005116017A1<\/a><\/td>\n | 24 May 2005<\/td>\n | 8 Dec 2005<\/td>\n | Astrazeneca Ab<\/td>\n | Process for the preparation of aryl substituted oxazolidinones as intermediates for antibacterial agents<\/td>\n<\/tr>\n |
\nWO2006038100A1<\/a><\/td>\n | 6 Oct 2005<\/td>\n | 13 Apr 2006<\/td>\n | Ranbaxy Lab Ltd<\/td>\n | Oxazolidinone derivatives as antimicrobials<\/td>\n<\/tr>\n |
\nWO2007023507A2<\/a><\/td>\n | 19 Jun 2006<\/td>\n | 1 Mar 2007<\/td>\n | Milind D Sindkhedkar<\/td>\n | Oxazolidinones bearing antimicrobial activity composition and methods of preparation<\/td>\n<\/tr>\n |
\nWO2007138381A2<\/a><\/td>\n | 13 Oct 2006<\/td>\n | 6 Dec 2007<\/td>\n | Delorme Daniel<\/td>\n | Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections<\/td>\n<\/tr>\n |
\nWO2010042887A2<\/a><\/td>\n | 9 Oct 2009<\/td>\n | 15 Apr 2010<\/td>\n | Trius Therapeutics<\/td>\n | Methods for preparing oxazolidinones and compositions containing them<\/td>\n<\/tr>\n |
\nWO2010091131A1<\/a><\/td>\n | 3 Feb 2010<\/td>\n | 12 Aug 2010<\/td>\n | Trius Therapeutics<\/td>\n | Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate<\/td>\n<\/tr>\n |
\nWO2010138649A1<\/a><\/td>\n | 27 May 2010<\/td>\n | 2 Dec 2010<\/td>\n | Trius Therapeutics, Inc.<\/td>\n | Oxazolidinone containing dimer compounds, compositions and methods to make and use<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n ……………………………………………………………………………………….<\/p>\n |